Image Credit: Medtronic
Medtronic announced that it received FDA’s approval of its BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), which personalize therapy based on a patient’s brain activity in real time – both in clinical settings and in daily life. aDBS is meant to automatically adjust therapy for symptom control, minimizing the need for patients to manually adjust stimulation.
BrainSense™ Adaptive DBS is available to Medtronic DBS patients with Parkinson’s who have been implanted with a Percept™ neurostimulator, as well as future Medtronic DBS patients.